Ratings Siemens Healthineers AG Deutsche Boerse AG

Equities

SHL

DE000SHL1006

Real-time Estimate Tradegate Other stock markets 07:56:34 28/05/2024 pm IST			5-day change	1st Jan Change
54.01 ^EUR	+0.69%		+1.84%	+2.11%

23/05	Ailing hospitals slow down German medical technology sector	DP
22/05	SIEMENS HEALTHINEERS : Berenberg maintains a Buy rating	ZD

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
With a 2024 P/E ratio at 29.78 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The company's enterprise value to sales, at 3.18 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
SIEMENS HEALTHINEERS AG	+2.11%	6.52TCr	-
THERMO FISHER SCIENTIFIC	+7.69%	22TCr	B
DANAHER CORPORATION	+13.14%	19TCr	B-
INTUITIVE SURGICAL, INC.	+18.59%	14TCr	B-
BOSTON SCIENTIFIC CORPORATION	+29.82%	11TCr	A-
EDWARDS LIFESCIENCES CORPORATION	+14.31%	5.3TCr	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.64%	5.03TCr	B+
AGILENT TECHNOLOGIES, INC.	+7.48%	4.42TCr	A
GE HEALTHCARE TECHNOLOGIES INC.	+2.46%	3.64TCr	-
RESMED, INC.	+21.43%	3.13TCr	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes